Form 8-K Receptos, Inc. For: Mar 03

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Form 8-K Receptos, Inc. For: Mar 03

Receptos (RCPT) Misses Q4 EPS by 13c

March 3, 2015 4:21 PM EST

Receptos (NASDAQ: RCPT) reported Q4 EPS of ($1.32), $0.13 worse than the analyst estimate of ($1.19).

Development Program Updates

Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (RMS)

After reporting positive results in the Phase 2 portion of the RADIANCE trial of ozanimod in RMS, Receptos initiated the second Phase 3 trial of ozanimod in RMS, called SUNBEAM. Similar to the RADIANCE Phase 3 trial, the SUNBEAM trial is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of ozanimod against interferon beta-1a (Avonex®) in approximately 1,200 patients with RMS. The primary objectives of the... More